Introduction
============

The formation of lymphatic vessels, whose main function is to drain interstitial fluid from the tissues back to the blood circulation, begins only after the blood circulation is already functional. The initial steps of lymphatic development are controlled by the transcription factors Sox18 and Prox1 and VEGF-C and its receptor VEGFR-3 ([@bib40]; [@bib16]; [@bib84]; [@bib35]; [@bib17]). Expression of Prox1 is induced by Sox18 in a restricted subset of endothelial cells in the embryonic jugular veins ([@bib84]; [@bib17]). These VEGF-C--responsive cells sprout and migrate to form the primary lymphatic sacs, which further remodel to form a primary lymphatic capillary plexus ([@bib78]; [@bib35]). The primary plexus undergoes further morphological and molecular changes to form a mature lymphatic network composed of lymphatic capillaries responsible for the uptake of lymph from the interstitial space and collecting lymphatic vessels that transport the lymph back to the blood circulation. Mature collecting vessels are characterized by a thin basement membrane, sparse pericyte coverage, and have intraluminal valves to prevent backflow of the fluid. Lymphatic capillaries, however, lack valves and a pericyte layer. These later steps of lymphatic vascular development, the maturation of the primary lymphatic plexus into functional collecting vessels and capillaries, are at present not well understood.

Loss of forkhead transcription factor *Foxc2* leads to defects in lymphatic remodeling, failure to form lymphatic valves, and increased pericyte coverage of lymphatic vessels ([@bib59]). In lymphedema-distichiasis (Online Mendelian Inheritance in Man reference no. 153400), a disease caused by mutations in *FOXC2*, the patients have a similar phenotype to *Foxc2^−/−^* mice with abnormal lymphatic vessel pericyte coverage ([@bib59]). Lymphedema-distichiasis patients also show reflux of tracer in a lymphoscintigram, indicating failure or absence of valves in their collecting lymphatic vessels ([@bib4]). Interestingly, a recent study shows linkage of *FOXC2* mutations to varicose veins and primary valve failure in veins, suggesting that FOXC2 controls the formation of venous valves ([@bib52]).

The transcription factor NFATc1 belongs to a family of calcium-sensitive transcription factors activated by calcineurin-dependent dephosphorylation (for review see [@bib11]). Activation of nuclear factor of activated T cells (NFAT) proteins results in exposure of a nuclear localization sequence and subsequent translocation to the nucleus. Once in the nucleus, NFATc1 interacts with other transcription factors, including AP-1, nuclear factor κB, Foxp3, and GATA, to form regulatory complexes on DNA ([@bib39]; [@bib55]; [@bib45]; [@bib81]; [@bib67]; [@bib3]). NFATc1 is implicated in the regulation of immune cells as well as in osteogenesis and hair follicle stem cells ([@bib44]; [@bib73]; [@bib27]). Studies of *NFATc1*-deficient mice have also revealed an essential role for NFATc1 in the morphogenesis of cardiac valves ([@bib14]; [@bib62]).

In this study, we have characterized the steps of lymphatic vascular maturation, which lead to the formation of two morphologically and molecularly distinct parts of the lymphatic vascular system: collecting lymphatic vessels and capillaries. We show that Foxc2 controls this process, and in the absence of Foxc2, lymphatic vessels fail to undergo transformation toward a lymphatic collecting vessel phenotype. Furthermore, we demonstrate that NFATc1 is a novel regulator of lymphatic vascular maturation and that it cooperates with Foxc2 in this process.

Results
=======

Molecular characterization of developing collecting lymphatic vessels
---------------------------------------------------------------------

To characterize the process of collecting lymphatic vessel formation, we studied morphological changes and the expression of the lymphatic endothelial-specific markers VEGFR-3, Foxc2, Prox1, and LYVE-1 in mouse mesenteric lymphatic vessels during development. The mesenteric lymphatic primordia can first be identified at embryonic day (E) 13.5 near the splenic and superior mesenteric veins ([@bib78]). At E14.5, staining for lymphatic endothelial receptor tyrosine kinase VEGFR-3 showed numerous isolated clusters or single lymphatic endothelial cells (LECs) extending long filopodia ([Fig. 1 A](#fig1){ref-type="fig"} and [Fig. S1 A](http://www.jcb.org/cgi/content/full/jcb.200901104/DC1)). These cell clusters, located on both sides along the mesenteric blood vessels, migrate and sprout toward each other along and across the blood vessels. By E15.5, LECs form a mesh-like network of highly branched capillary-like vessels surrounding the mesenteric arteries and veins ([Fig. 1 B](#fig1){ref-type="fig"}). After E15.5, the mesenteric lymphatic capillary plexus undergoes substantial morphological changes, leading to formation of collecting lymphatic vessel trunks by E17.5, characterized by even diameter, presence of intraluminal valves, and absent or little branching ([Fig. 1, C and D](#fig1){ref-type="fig"}). These features become even more pronounced in the postnatal collecting vessels ([Fig. 1 E](#fig1){ref-type="fig"}).

![**Expression of lymphatic endothelial markers during formation of collecting lymphatic vessels.** (A--T) Whole-mount immunofluorescent staining of wild-type mesenteric vessels at the indicated ages for VEGFR-3 (A--E), Foxc2 (F--J and P--T), and Prox1 (K--O and P--T). At E14.5, Foxc2 is expressed in a few LECs (arrow), whereas arterial SMCs are Foxc2 positive (arrowhead). (U) Schematic summary of the expression of lymphatic markers during lymphatic collecting vessel maturation. Bars, 100 µm.](JCB_200901104_RGB_Fig1){#fig1}

On the molecular level, E14.5--15.5 lymphatic vessels express uniformly high levels of Prox1 and VEGFR-3 ([Fig. 1, A and K](#fig1){ref-type="fig"}). At E14.5, LYVE-1 expression was absent in lymphatic vessels in the skin, whereas the lymph sacs show high LYVE-1 expression (Fig. S1, B--E). Interestingly, in the mesenterium, only a small subset of LECs express LYVE-1 at this time point (Fig. S1, G and L). At E14.5, Foxc2 is mainly expressed in arterial smooth muscle cells (SMCs), and Foxc2 levels are high only in a few isolated LECs ([Fig. 1 F](#fig1){ref-type="fig"}). Strikingly, by E15.5, all LECs express high levels of Foxc2 ([Fig. 1 G](#fig1){ref-type="fig"}). Up-regulation of Foxc2 expression is followed by an increase in LYVE-1 levels, which becomes present in all LECs by E16.5 (Fig. S1, H--N). Between E15.5 and 16.5, the expression of first Foxc2 and then Prox1 begins to decrease except in the areas of characteristic constrictions, which delineate forming lymphatic valves, and by E17.5, only weak expression can be detected in the lymphangion segments between the valves ([Fig. 1, G--J, L--O, and Q--T](#fig1){ref-type="fig"}). Foxc2 and Prox1 down-regulation is followed by a decrease of VEGFR-3 and LYVE-1 at E17.5--postnatal day (P) 9, but VEGFR-3 remains high in the valve leaflets, whereas LYVE-1 expression becomes very low in all collecting LECs, as it has been reported previously ([Fig. 1, D and E](#fig1){ref-type="fig"}; and Fig. S1, J, K, O, and P; [@bib46]). In the fully mature postnatal collecting lymphatic vessels, the expression of Foxc2, Prox1, and VEGFR-3 in vessel trunks is even weaker, whereas the expression in the valves remains high.

The presence of a thin basement membrane and a sparse coating with mural cells is another characteristic feature of collecting lymphatic vessels. We found that accumulation of basement membrane protein collagen IV starts at E16.5 ([Fig. 2, A--J](#fig2){ref-type="fig"}). NG2-positive mural cells start to appear around the forming collecting vessels at E17.5, whereas α smooth muscle actin (SMA)--positive SMCs are prominent only after birth ([Fig. 2, A--E and K--X](#fig2){ref-type="fig"}).

![**Formation of basement membrane and mural cell coating during maturation of lymphatic collecting vessels.** (A--X) Whole-mount immunofluorescent staining of wild-type mesenteric vessels at the indicated ages for VEGFR-3 (A--E), collagen IV (F--J), SMA (K--O), and NG2 (P--X). Accumulation of basement membrane to collecting lymphatic vessels occurs at E16.5 (C and H, arrows), whereas recruitment of SMCs occurs between E17.5 and P9 (E and O, arrows), and NG2-positive mural cells appear around the vessels at E17.5 (R and V, arrows). Bars, 100 µm.](JCB_200901104_RGB_Fig2){#fig2}

In summary, the formation of lymphatic collecting vessels starts at E14.5--15.5, which is coincident with up-regulation of Foxc2 ([Fig. 1 U](#fig1){ref-type="fig"}). This is followed by remodeling of the primary capillary plexus and formation of a single lymphatic trunk, at which point the expression of Foxc2 decreases except in the areas of the forming lymphatic valves, and is further followed by a decrease in Prox1, VEGFR-3, and LYVE-1 expression. Accumulation of basement membrane proteins starts at E16.5 followed by recruitment of NG2-positive mural cells at E17.5 and SMCs postnatally. These data uncover a highly dynamic spatiotemporal expression profile for LEC markers during the formation and maturation of collecting lymphatic vessels and suggest that the change in Foxc2 expression is the critical first event of the maturation process.

Loss of Foxc2 prevents formation of collecting lymphatic vessels
----------------------------------------------------------------

Up-regulation of Foxc2 at E15.5, which precedes the morphological and molecular changes in the maturing lymphatic network, suggested that Foxc2 controls lymphatic vascular maturation. Indeed, in *Foxc2^−/−^* mice, lymphatic vessels fail to down-regulate Prox1, VEGFR-3, and LYVE-1 ([Fig. 3](#fig3){ref-type="fig"}). In contrast, the collecting vessels in the mesentery of E17.5 heterozygous littermates show a normal expression pattern with low levels of VEGFR-3 and Prox1 in the lymphangion, high expression in the valves ([Fig. 3, A and E](#fig3){ref-type="fig"}), and uniformly low expression of LYVE-1 throughout the whole collecting vessel ([Fig. 3 G](#fig3){ref-type="fig"}). The lymphatic capillaries continue to express high levels of LYVE-1 both in *Foxc2^−/−^* mice and in heterozygous littermates ([Fig. 3, G and H](#fig3){ref-type="fig"}). The secondary lymphoid chemokine (SLC) is also highly expressed in the immature collecting vessels in *Foxc2^−/−^* mice, whereas it is present only in the valves of the collecting vessels of *Foxc2*^+/+^ mice ([Fig. 3, I and J](#fig3){ref-type="fig"}). In addition, the collecting vessels in *Foxc2^−/−^* mice are more highly branched, which may reflect incomplete intussusceptive vascular pruning ([@bib6]).

![**Foxc2 is essential for the formation of collecting lymphatic vessels.** (A--J) Mesenteric lymphatic vessels fail to down-regulate VEGFR-3, Prox1, and SLC in the absence of Foxc2. Whole-mount immunofluorescent staining for VEGFR-3 (A--D), Prox1 (E and F), LYVE-1 (G and H), and SLC (I and J) in E17.5 *Foxc2*^−/−^ or control embryos. (C and D) Internalization of VEGFR-3 in lymphatic vessels of *Foxc2^−/−^* mice but not control E17.5 embryos. (K and L) Increased *Angpt2* expression in lymphatic vessels of *Foxc2^−/−^* mice. In situ hybridization for *Angpt2* (blue) and immunohistochemical staining for VEGFR-3 (red). Arrows, lymphatic valves (A, E, and I) or collecting lymphatic vessels (G and H); arrowheads, lymphatic capillaries; dashed lines, lymphatic vessels. Bars: (A, B, and E--J) 100 µm; (C, D, K, and L) 25 µm.](JCB_200901104_RGB_Fig3){#fig3}

Activation of VEGFR-3 after binding to its ligand VEGF-C is followed by internalization of the receptor observed in cultured LECs and in sprouting lymphatic capillaries in vivo ([@bib48]; [@bib79]; [@bib86]). We observed uniform membranous staining for VEGFR-3 in wild-type collecting vessels, which is consistent with a quiescent VEGF-C--VEGFR-3 pathway ([Fig. 3 C](#fig3){ref-type="fig"}). In contrast, VEGFR-3 in *Foxc2^−/−^* mice was concentrated in grainy dots and largely absent from the cell surface, which is similar to sprouting lymphatic capillaries ([Fig. 3 D](#fig3){ref-type="fig"} and Fig. S1 F). Although the exact reason for the increased VEGFR-3 internalization remains to be investigated, it is indicative of active VEGFR-3 signaling and further confirms the failure of *Foxc2^−/−^* lymphatic vessels to adopt a collecting vessel phenotype. Angiopoietin-2 (Ang2 and *Angpt2*), a ligand of Tie2 endothelial receptor tyrosine kinase, is important in the regulation of blood vascular maturation and stabilization but is also essential for normal lymphatic development. *Angpt2*-deficient mice display disorganized and hypoplastic lymphatic capillaries and an aberrant recruitment of periendothelial cells to lymphatic capillaries ([@bib19]; [@bib71]; [@bib15]). Ang2 is produced by LECs in vivo ([Fig. S2 F](http://www.jcb.org/cgi/content/full/jcb.200901104/DC1); [@bib15]), and its expression is induced in cultured LECs upon treatment with VEGF-C ([@bib80]). In agreement with the increased VEGFR-3 internalization, we observed higher levels of *Angpt2* in *Foxc2*-deficient lymphatic endothelia ([Fig. 3, K and L](#fig3){ref-type="fig"}). Activation of VEGFR-3 also leads to enhanced sprouting of lymphatic capillaries, accompanied by formation of filopodia ([@bib65]; [@bib86]). We observed abundant lymphatic sprouting in the developing lymphatic vasculature in the skin of wild-type mice ([Fig. 4, A--E](#fig4){ref-type="fig"}). In contrast, *Foxc2^−/−^* lymphatic vessels contained numerous blunt-ended protrusions devoid of filopodia, which were closely associated with a surrounding layer of basement membrane protein collagen IV ([Fig. 4, F--J](#fig4){ref-type="fig"}).

![**Defective sprouting of lymphatic vessels in *Foxc2^−/−^* mice.** (A--J) Whole-mount immunofluorescent staining for VEGFR-3 (green), LYVE-1 (red), and collagen IV (white) of skin from E17.5 wild-type and *Foxc2^−/−^* embryos. Note the close association of collagen IV and aborted sprouts in *Foxc2^−/−^* lymphatic vessels (I and J), whereas no collagen is deposited around wild-type lymphatic vessels (D and E). Bars: (A and F) 100 µm; (B--E and G--J) 50 µm.](JCB_200901104_RGB_Fig4){#fig4}

Collectively, our data show that loss of *Foxc2* leads to a failure in the maturation of the primary lymphatic plexus into functional collecting lymphatic vessels and capillaries. Instead, the *Foxc2^−/−^* lymphatic vasculature is characterized by a persistent expression of the lymphatic capillary markers Prox1, VEGFR-3, LYVE-1, and SLC, failure to down-regulate VEGFR-3 signaling, and abnormal capillary sprouting.

NFATc1 is expressed in LECs and is controlled by PROX1 and VEGF-C
-----------------------------------------------------------------

Failure to form intraluminal valves is a characteristic feature of *Foxc2^−/−^* lymphatic vessels ([@bib59]), which led us to investigate the potential for cooperation between Foxc2 and pathways implicated in the regulation of heart valve development such as Wnt and NFAT ([@bib1]). We did not observe β-galactosidase expression in the lymphatic valves of the Wnt reporter mice TOP-Gal or BAT-Gal, whereas strong LacZ staining was observed in cardiac valves as reported previously ([@bib12]; [@bib50]; unpublished data). Similarly, reporter expression was not modified in the absence of *Foxc2* in TOP-Gal;*Foxc2^−/−^* or BAT-Gal;*Foxc2^−/−^* mice (unpublished data).

However, for NFATc1, we detected previously unsuspected expression and activity in the lymphatic vasculature. At E12.5, nuclear NFATc1 was present in LECs of the lymph sacs. At E13.5, NFATc1 was mainly detected in the cytoplasm and, at lower levels, in the nuclei of endothelial cells of the lymph sacs. Mostly nuclear localization was observed from E14.5 onwards ([Fig. 5, A--H](#fig5){ref-type="fig"}). Notably, no significant expression of NFATc1 was detected in blood vessels at E12.5--17.5 nor in other Prox1-expressing tissues, such as the spinal cord (Fig. S2, B and C; unpublished data), suggesting a LEC-specific function in addition to the previously described role in endocardial cells ([@bib14]; [@bib62]; [@bib8]). The in situ hybridization analysis demonstrated expression of *NFATc1* in lymphatic vessels, especially in the valves, further confirming our observations (Fig. S2, D--F). A more detailed analysis of Foxc2 and NFATc1 expression revealed that these transcription factors are present only in a subset of LECs and are largely coexpressed as determined by double staining (Fig. S2 G). Moreover, in embryonic and adult skin, Foxc2 expression is mainly detected in lymphatic collecting vessels, but not in capillaries, further confirming that Foxc2 is a regulator of collecting vessel identity (Fig. S2, H--J; unpublished data).

![**Expression and regulation of NFATc1 in LECs.** (A--H) Immunofluorescent staining for NFATc1 (green), Prox1 (red), and DNA (blue) at E12.5--17.5. Arrowheads, cytoplasmic staining. (I) Western blotting for the indicated proteins of iLECs transfected with PROX1 siRNA, control siRNA, or iLECs and control cell line SW480A (a subclone of colon carcinoma cell line) transduced with AdPROX1 or control AdLacZ. (J and K) NFATc1 activation is VEGF-C and VEGFR-2 dependent. Cells were stimulated with the indicated growth factors or BSA in the presence and absence of CsA and stained for NFATc1 (red) and PROX1 (green). (J) Quantification of nuclear intensity of NFATc1 in iLECs. Data are presented as mean percentual nuclear intensity ± SEM. \*\*, P \< 0.001. RU, relative intensity unit. Bars, 20 µm.](JCB_200901104_RGB_Fig5){#fig5}

Because of the specific expression of NFATc1 in lymphatic but not blood vascular endothelial cells, we investigated the potential regulation of NFATc1 expression by PROX1, which controls LEC commitment ([@bib60]; [@bib83]). Indeed, overexpression of PROX1, using adenoviral gene transfer in primary human intestinal LECs (iLECs), increased NFATc1 levels, whereas PROX1 overexpression in nonendothelial cells did not have any effect on NFATc1 expression ([Fig. 5 I](#fig5){ref-type="fig"}). Consistently, siRNA-mediated knockdown of PROX1 resulted in decreased NFATc1 levels ([Fig. 5 I](#fig5){ref-type="fig"}).

VEGF stimulates nuclear translocation of NFATc1 and increases proliferation in human pulmonary valve endothelial cells ([@bib32]). This led us to investigate whether VEGF-C, which has been shown to promote the formation of collecting vessels in addition to its role in lymphatic endothelial proliferation and sprouting ([@bib74]), can activate NFATc1 in LECs. Indeed, treatment of iLECs with VEGF-C resulted in strong accumulation of nuclear NFATc1, whereas control BSA-treated cells showed only little nuclear NFATc1 staining ([Fig. 5, J and K](#fig5){ref-type="fig"}). VEGF-E, a viral homologue of VEGF that signals through VEGFR-2 ([@bib57]; [@bib53]), also increased nuclear NFATc1, whereas VEGF-C156S, a mutant form of VEGF-C that unlike wild-type VEGF-C does not bind to VEGFR-2 but only to VEGFR-3 ([@bib34]), did not have a marked effect on nuclear accumulation of NFATc1 in spite of the activation of ERK1/2 phosphorylation ([Fig. 5, J and K](#fig5){ref-type="fig"}; and [Fig. S3 A](http://www.jcb.org/cgi/content/full/jcb.200901104/DC1)). In contrast to its effect on nuclear translocation of NFATc1, VEGF-C treatment did not increase *NFATc1* mRNA levels (Fig. S3 B), and conversely, overexpression of PROX1 in LECs did not lead to a specifically nuclear increase in NFATc1 but rather to increased overall protein levels (Fig. S3 C). Collectively, our data indicate that NFATc1 is expressed in a subset of LECs and that its levels are controlled by PROX1, whereas its activity and nuclear translocation are regulated by VEGF-C through activation of VEGFR-2 or VEGFR-2--VEGFR-3 heterodimers.

Inhibition of NFAT signaling prevents formation of collecting lymphatic vessels
-------------------------------------------------------------------------------

Next, we studied whether inhibition of NFATc1 signaling affects lymphatic vascular development in vivo. The initial LEC commitment was not affected in mice deficient in *Nfatc1*, as determined by staining for Prox1 (unpublished data). However, lymphatic capillaries in mice surviving until E15.5 were abnormally patterned, tortuous, and widened, which is reminiscent of the lymphatic vessels in *Foxc2*^−/−^ mice ([Fig. 6, A and B](#fig6){ref-type="fig"}). These data suggested that NFATc1 controls the remodeling steps of lymphatic vascular development. Because *Nfatc1^−/−^* mice die before the formation of fully mature collecting lymphatic vessels ([@bib14]; [@bib62]), we treated mice with cyclosporine A (CsA), an inhibitor of calcineurin activity, and thus dephosphorylation and nuclear translocation of NFAT transcription factors ([@bib21]). CsA treatment at E11 reproduces the cardiac valve defects seen in *Nfatc1^−/−^* mice, whereas CsA administration at E12 does not affect the heart valves or the viability of the embryos ([@bib8]). To avoid interference with heart development, we treated wild-type and *Foxc2*^+/−^ pregnant females at E12.5--16.5 and analyzed the vasculature at E17.5. As expected ([@bib8]), CsA reduced the nuclear localization of NFATc1 in LECs (Fig. S2, K--N), but it did not affect the viability and overall appearance of the embryos ([Fig. 6 C](#fig6){ref-type="fig"}). Similarly, the blood vasculature of CsA-treated embryos did not differ from that of the control mice and displayed normal formation of veins, arteries, and capillary bed, appropriate coverage with SMCs, and normal blood vascular density ([Fig. 6, D--K](#fig6){ref-type="fig"}; unpublished data).

![**Defective lymphatic and normal blood vessel development upon loss of NFAT signaling.** (A and B) Abnormal lymphatic vessel patterning in *NFATc1^−/−^* embryos. Whole-mount immunofluorescent staining of E15.5 skin for LYVE-1. Bars, 200 µm. (C) Normal macroscopic appearance of E17.5 embryos after administration of CsA. (D--K) Normal blood vessel morphology and SMC coverage after administration of CsA. Whole-mount immunofluorescent staining for PECAM-1 (green) and SMA (red) of control and CsA-treated skin and mesenteric vessels of E17.5 wild-type, *Foxc2^+/−^*, and *Foxc2^−/−^* embryos. Mesent, mesentery. Bars: (skin) 200 µm; (mesentery) 100 µm.](JCB_200901104_RGB_Fig6){#fig6}

In contrast, CsA treatment resulted in abnormal lymphatic vessel patterning, lymphatic vessel hyperplasia, defective remodeling of mesenteric collecting vessels, and recruitment of SMCs to dermal lymphatic capillaries ([Fig. 7, A--P and Q](#fig7){ref-type="fig"}; and [Fig. 8, A--H](#fig8){ref-type="fig"}), which are phenotypes consistent with the early remodeling defects observed in *Nfatc1*^−/−^ mice and reminiscent of the phenotype of *Foxc2^−/−^* mice. These defects were especially pronounced in the lymphatic vessels of CsA-treated *Foxc2*^+/−^ embryos ([Fig. 7, K--P](#fig7){ref-type="fig"}). Furthermore, the lymphatic vessels of CsA-treated mice failed to down-regulate VEGFR-3, Prox1 ([Fig. 7, A--P](#fig7){ref-type="fig"}), and LYVE-1 (unpublished data), and CsA-treated *Foxc2*^+/−^ mice completely lacked lymphatic valves, whereas CsA-treated wild-type mice had a significantly reduced number of valves ([Fig. 7, F, N, P, and R](#fig7){ref-type="fig"}). Similar to lymphatic vessels in *Foxc2^−/−^* mice, we also observed increased internalization of VEGFR-3 ([Fig. 8, I--L](#fig8){ref-type="fig"}) and higher *Angpt2* levels ([Fig. 8, M and N](#fig8){ref-type="fig"}). The blunt aborted sprouts seen in the lymphatic capillaries of *Foxc2^−/−^* mice were also present in CsA-treated *Foxc2*^+/−^ mice ([Fig. 7 O](#fig7){ref-type="fig"}). Injection of FITC-dextran into the hind limbs of E17.5 *Foxc2*^+/−^ CsA-treated embryos demonstrated abnormal outflow from the collecting lymphatic vessels to the precollector vessel branches, whereas only the collecting lymphatic vessel trunks were visualized in control embryos, further confirming loss of collecting vessel function ([Fig. 7, S and T](#fig7){ref-type="fig"}). Foxc2 was present in all LECs of CsA-treated mice, demonstrating that NFAT signaling does not control Foxc2 expression or protein stability (Fig. S2, O and P), thus, the lymphatic defects are not caused by the lack of Foxc2. Conversely, *Foxc2^−/−^* mice showed normal NFATc1 expression (unpublished data).

![**NFAT signaling is necessary for the formation of collecting lymphatic vessels.** (A--P) NFAT inhibition prevents maturation of lymphatic vessels. Whole-mount immunofluorescent staining for VEGFR-3 (green) and Prox1 (red) of mesenteries and skins of control (A--H) or CsA-treated (I--P) E17.5 embryos. Arrows, lymphatic valves. (Q) Quantification of mean lymphatic vessel width from control and CsA-treated E17.5 dermal lymphatic capillaries (*n* = 4). (R) Quantification of mesenteric lymphatic valves. *n* = 4 per genotype. \*, P \< 0.005; \*\*, P \< 0.001. (S and T) Lymph backflow in CsA-treated embryos. Collecting lymphatic vessels were visualized after high molecular weight FITC-dextran injection into E17.5 embryos. Data are presented as mean ± SEM. Bars: (A--D and J--L) 100 µm; (E--H and M--P) 200 µm; (S and T) 500 µm.](JCB_200901104_RGB_Fig7){#fig7}

![**Inhibition of NFAT signaling in vivo prevents maturation of collecting lymphatic vessels.** (A--H) Ectopic SMCs in lymphatic capillaries of *Foxc2^−/−^* and CsA-treated embryos. Whole-mount immunofluorescent staining for SMA (red) and Prox1 (green) of embryonic skin at E17.5. Arrows, SMA-positive lymphatic vessels. (I--L) Increased VEGFR-3 internalization in lymphatic vessels of CsA-treated *Foxc2^+/−^* embryos. Whole-mount immunofluorescent staining for VEGFR-3 (green/gray) and Prox1 (red). (M and N) Increased expression of *Angpt2* upon inhibition of NFAT signaling. In situ hybridization for *Angpt2* (blue) and immunohistochemical staining for VEGFR-3 (red) at E17.5. Boxed areas indicate regions shown at higher magnifications in J and L. Bars: (A--L)100 µm; (M and N) 25 µm.](JCB_200901104_RGB_Fig8){#fig8}

Collectively, these data show that suppression of NFATc1 activation during the late stages of embryogenesis prevents the formation and maturation of collecting lymphatic vessels without affecting blood vascular development in a manner highly reminiscent of the *Foxc2* knockout phenotype. Moreover, loss of one *Foxc2* allele strongly potentiates the effects of NFAT pathway inhibition. Together with the colocalization of Foxc2 and NFATc1 in developing collecting vessels, this suggests a functional cooperation between these two signaling cascades.

ChIP-chip analysis of FOXC2-binding sites reveals cooperation with NFAT signaling
---------------------------------------------------------------------------------

The similarities between the lymphatic maturation defects in Foxc2-deficient mice and mice with inhibited NFATc1 signaling led us to investigate a possible link between FOXC2 and NFATc1. FOXC2 and NFATc1 coimmunoprecipitated, indicating that the two transcription factors physically interact at least when overexpressed (Fig. S3 D). To gain a mechanistic understanding of the FOXC2-mediated transcriptional network, we performed genome-wide location analysis of endogenous FOXC2 in primary LECs. We used chromatin immunoprecipitation (ChIP) coupled with tiling microarrays covering the entire human genome (ChIP-chip) to produce an unbiased high resolution map of FOXC2-binding sites. For each ChIP-chip biological replicate, the immunoprecipitation was verified by Western blotting with anti-FOXC2 antibody ([Fig. S4 A](http://www.jcb.org/cgi/content/full/jcb.200901104/DC1)). ChIP DNA was amplified using the whole genome amplification method, which introduces very little bias compared with a commonly used linker-mediated PCR procedure ([@bib56]). A total of 2350 FOXC2-binding sites were identified in LECs at a false discovery rate (FDR) of 0.1% ([Fig. 9](#fig9){ref-type="fig"} and [supplemental data](http://www.jcb.org/cgi/content/full/jcb.200901104/DC1)). Because low yields of ChIP DNA from primary LECs precluded large-scale validation of ChIP-chip results by quantitative PCR, we used an alternative validation strategy by electrophoretic mobility shift assay (EMSA). We PCR amplified ∼200-bp fragments from nine randomly selected ChIP peak regions (Fig. S4 D) and tested them in EMSA with nuclear extracts from LECs transduced with FOXC2- (AdFOXC2) or control β-galactosidase--expressing adenoviruses (AdLacZ). The selection of ChIP regions was unbiased with respect to model-based analysis of tiling array (MAT) score, p-value, FDR, or fold change. As expected, FOXC2 formed stable complexes with all ChIP region fragments but not with the control glyceraldehyde 3-phosphate dehydrogenase (GAPDH) fragment, and no specific complexes were observed with control nuclear extracts from cells transduced with AdLacZ ([Fig. 9 B](#fig9){ref-type="fig"}). The FOXC2--DNA complexes could be supershifted with anti-FOXC2 but not control antibodies (Fig. S4 B; unpublished data), and point mutations in the forkhead-binding motif totally abolished the probe interaction with FOXC2 (Fig. S4 C).

![**Location analysis of FOXC2-binding sites in LECs.** (A) Visualization of several FOXC2-binding regions. MAT score for each tiling array probe is shown in blue. Purple bars indicate FOXC2-enriched regions. Red peaks indicate ChIP regions selected for validation by EMSA. Potential target genes are indicated below the enrichment profile. Vertical lines, exons; horizontal lines, introns. Arrowheads indicate the direction of transcription. (B) Validation of ChIP-chip results. ^33^P-labeled 200-bp DNA probes from selected ChIP regions ([Fig. S4 D](http://www.jcb.org/cgi/content/full/jcb.200901104/DC1)) were incubated with nuclear extracts from LECs transduced with FOXC2-expressing (AdFOXC2) or control adenovirus (AdLacZ), and the resulting DNA--protein complexes were analyzed by EMSA. GAPDH probe was used as a negative control. (C) Distribution of FOXC2-binding sites in the human genome. ChIP regions were mapped to their nearest RefSeq genes using CEAS ([@bib31]). Proximal promoters and immediate downstream regions were defined as ≤1 kb upstream from the transcription start site or ≤1 kb downstream from the 3′ end of a gene, respectively. Distal intergenic refers to all locations outside the boundaries of a gene and the 1 kb flanking the gene on either end. UTR, untranslated region. (D) FOXC2-binding regions are conserved among higher eukaryotes. ChIP regions were uniformly expanded to 3 kb, aligned at the center, and the mean phastCons conservation score ([@bib72]) was retrieved from the University of California Santa Cruz genome resource (<http://genome.ucsc.edu>) for each aligned position. The mean phastCons score was plotted against the distance from ChIP region center (1.5 kb upstream and downstream). (E) Comparison of a novel FOXC2-binding motif identified by MEME analysis of ChIP-chip data with the Freac-3 (FOXC1) motif from the TRANSFAC database. The region of similarity is boxed. Chr, chromosome.](JCB_200901104_RGB_Fig9){#fig9}

Analysis of ChIP-chip data revealed that \>90% of FOXC2-binding sites were located in distal intergenic regions and gene introns, and \<1% of sites were located in the proximal promoter regions ([Fig. 9 C](#fig9){ref-type="fig"}). Notably, there was a high degree of conservation of FOXC2-binding sites among higher eukaryotes ([Fig. 9 D](#fig9){ref-type="fig"}), suggesting that the FOXC2-regulated transcriptional network in lymphatic vascular development is conserved across species.

De novo motif discovery analysis revealed a common sequence motif in ChIP regions, which strongly resembled that of Freac-3 (FOXC1) from the TRANSFAC database. Both the newly discovered motif and the Freac-3 motif contained the 3′-terminal forkhead-binding element (T/A/C)AAACA preceded by an adenine-rich tract ([Fig. 9 E](#fig9){ref-type="fig"}). Such similarity between the two motifs is in good agreement with the fact that Freac-3/FOXC1 and FOXC2 have nearly identical DNA-binding domains ([@bib68]). The motifs, however, were completely different further upstream, which likely reflects fundamentally different approaches used for their identification. The Freac-3 motif has been identified by in vitro PCR selection using GST-tagged DNA-binding domain of FOXC1 ([@bib61]), whereas the motif discovered in this study was derived from ChIP-chip experiments performed with endogenous FOXC2 in primary cells.

We further studied whether the ChIP-chip data could suggest an explanation for the observed physical interaction of FOXC2 and NFATc1 as well as for their functional cooperation in the in vivo models. We performed enrichment analysis of all human transcription factor--binding sites from the TRANSFAC database in the FOXC2 ChIP sequences. NFAT-binding sites were significantly enriched (M00302, 2.07 fold change and 95% confidence interval \[1.96; 2.19\]; M00935, 1.95 fold change \[1.84; 2.07\]), whereas no statistically significant enrichment was seen for any of the control transcription factors ([Fig. 10 A](#fig10){ref-type="fig"}). Similarly, no enrichment was observed for transcription factors specifically expressed in endothelial cells (GATA2; [@bib38]) or in LECs (SOX18, MEF2C, or PROX1; [@bib84]; [@bib82]; [@bib17]; unpublished data). 86% of the FOXC2 ChIP sequences were found to contain at least one NFAT consensus sequence using a threshold of 3.4, which detects FOXC2-binding sites in 80% of the ChIP sequences ([Table S1](http://www.jcb.org/cgi/content/full/jcb.200901104/DC1)). Further experimental validation of the randomly selected ∼200-bp fragments from FOXC2 ChIP peak regions (Fig. S4 D) by EMSA revealed that NFATc1 strongly interacted with fragments 3, 4, 7, and 8 but not with fragments 1, 2, 5, 6, and 9. This observation was in agreement with the presence of NFAT consensus sites in the fragments 3, 4, 7, and 8 ([Fig. 10 B](#fig10){ref-type="fig"}; unpublished data). We next tested the fragments in luciferase reporter analysis and found that fragment 8 showed synergistic activation in the presence of both NFATc1 and FOXC2 compared with weak activation when either transcription factor was present alone ([Fig. 10 C](#fig10){ref-type="fig"}). Interestingly, the NFATc1-dependent activation of the reporter fragment 3 was partially repressed by FOXC2, whereas activity of reporter fragments 1 and 2 was not modified. The absence of response to FOXC2 of the reporters 1 and 2 could be a result of the fact that some 200-bp ChIP fragments may lack control elements needed for the efficient transcriptional regulation in our reporter system, or, alternatively, only the fragments that harbor both NFAT- and FOXC2-binding sites are capable of directing transcription. To investigate the mechanisms of transcriptional regulation by FOXC2 and NFATc1 in more detail, we performed site-directed mutagenesis of the reporter fragment 8, which contained three potential FOXC2-binding sites and one NFAT-binding site. Inactivation of FOXC2 site 1 proximal to the NFAT site significantly reduced the response to NFATc1, whereas mutations of more distal FOXC2 sites 2 and 3 had less pronounced effects ([Fig. 10 D](#fig10){ref-type="fig"}). These results suggest that FOXC2 binding is required for further reporter activation by NFATc1.

![**Cooperation of FOXC2 and NFATc1 signaling.** (A) Enrichment of FOXC2- and NFATc1-binding sites in ChIP sequences. Red points indicate the number of sites observed in the original ChIP sequences, showing that both FOXC2 (de novo--discovered matrix)- and NFAT (M00302 and M00935)-binding sites are highly enriched compared with the randomized sequences. PAX6 (M0097), CEBPB (M00109), ATF3 (M00513), BCL6 (M01183), and MYCMAX (M00322) are shown as examples of nonenriched sites. (B) NFATc1 interacts with a subset of FOXC2 ChIP regions. ^33^P-labeled DNA probes of ∼200 bp from selected ChIP peak regions ([Fig. S4 D](http://www.jcb.org/cgi/content/full/jcb.200901104/DC1)) were incubated with recombinant NFATc1 protein together with anti-NFATc1 or control antibodies, and the resulting DNA--protein complexes were analyzed by EMSA. (C) Coregulation by FOXC2 and NFATc1. Selected ∼200-bp fragments of ChIP peak regions (Fig. S4 D) were subcloned into a pTA-luc luciferase reporter, and the luciferase activity was analyzed after cotransfection with either empty expression vector, expression vectors for FOXC2 or NFATc1, or both FOXC2 and NFATc1. (D) Mutations in FOXC2-binding sites reduce coactivation by NFATc1. Luciferase activity was analyzed after cotransfection of wild-type (WT) or mutated fragment 8/pTA-luc luciferase reporters with either empty expression vector, expression vectors for FOXC2 or NFATc1, or cotransfection with both FOXC2 and NFATc1. Data are presented as the mean ± SD.](JCB_200901104_RGB_Fig10){#fig10}

In summary, we have identified FOXC2-binding sites in primary LECs using an unbiased genome-wide location mapping approach and showed that a subset of these regions is enriched in NFAT-binding sites. In addition, we demonstrated that NFATc1 and FOXC2 interact with ChIP-derived DNA and that these two transcription factors can cooperate in the regulation of transcription. Collectively, these data provide a molecular basis for the observed in vivo cooperation between the NFATc1 and FOXC2 signaling in the developing lymphatic vasculature.

Discussion
==========

Blood vessel maturation, which starts with establishment of the venous-arterial identity and continues with the remodeling by sprouting, splitting, fusion, and pruning of preexisting vessels, recruitment of mural cells, and the deposition of a basement membrane and a perivascular ECM, has been extensively studied over recent years ([@bib63]; [@bib30]; [@bib69]; [@bib13]; [@bib9]; [@bib42]). However, much less is known about the corresponding developmental process in the lymphatic vasculature. In this study, we describe the morphological and molecular changes that lead to the formation of the collecting lymphatic vessels during development. We conclude that the transcription factors FOXC2 and NFATc1 control this process and are responsible for establishing a collecting lymphatic vessel identity by binding to proximal sites on the DNA and regulating expression of downstream genes.

Discovery of lymphatic endothelial specific markers and molecular regulators, such as Prox1, VEGF-C--VEGFR-3, Foxc2, and LYVE-1, has significantly advanced our understanding of lymphatic vascular biology ([@bib58]; [@bib47]). In this study, we show that the specialization of lymphatic vessels into collecting vessels and capillaries is characterized by down-regulation of lymphatic capillary markers LYVE-1, VEGFR-3, and SLC ([@bib46]; and this study), which is preceded by changes in the expression pattern of the transcription factors Foxc2 and Prox1. The role of LYVE-1 and SLC down-regulation in collecting lymphatic vessel function remains to be investigated. In contrast, down-regulation of VEGFR-3 is likely to be important for the establishment of a quiescent phenotype of collecting lymphatic vessels, which act essentially as lymph conduits, whereas lymphatic capillaries continue to express high levels of VEGFR-3 and serve as primary sites of lymphangiogenic response ([@bib86]). Such balance in response to VEGF-C signaling would also be important to ensure maximally efficient lymph transport. Accumulation of ECM and basement membrane components, as well as recruitment of pericytes and SMCs, is a relatively late event in the establishment of a collecting vessel identity, which follows the changes in gene expression in the lymphatic endothelium. Interestingly, VEGFR-3, Prox1, and Foxc2 levels remain high in the developing and adult intraluminal valves, suggesting that valve LECs are molecularly distinct from the nearby cells in the collecting vessel trunk, perhaps as a result of distinct mechanosensory transduction in these two regions and the need for the constant repopulation of endothelial cells in the valves.

Sharp up-regulation of Foxc2 at E15--15.5 is the earliest observed event during the formation of collecting vessels. Furthermore, genetic loss of *Foxc2* leads to failure in the remodeling and the accompanying down-regulation of Prox1, VEGFR-3, LYVE-1, and SLC in maturing lymphatic vessels, which instead remain in an immature capillary-like state. Studies of the blood vasculature have demonstrated a functional separation of endothelial cells in angiogenic sprouts into stalk cells and tip cells, the latter characterized by extensive formation of filopodia, which is important for correct vessel guidance and establishment of a properly patterned vascular network in response to a VEGF gradient ([@bib20]). In this study, we show that in spite of excessive VEGFR-3 expression and lymphatic vessel hyperplasia, the *Foxc2*-deficient capillary plexus is paradoxically characterized by defective sprouting. Although the exact cause remains to be investigated, this is possibly a result of abnormal deposition of collagen IV around nascent tip cells, which could prevent formation of tip cell filopodia and normal vessel guidance and patterning. An important remaining question concerns the signals controlling Foxc2 expression in the developing lymphatic vasculature; studies from other cell types show that TGF-β or BMP2 can induce FOXC2 in vitro ([@bib87]; [@bib49]). Future studies of mice with conditional ablation of TGF or bone morphogenetic proteins signaling components in the lymphatic endothelium should clarify the contribution of these pathways to Foxc2 regulation.

In search of similarities between the molecular mechanisms of cardiac and lymphatic valve formation, we found that NFATc1, a transcription factor that controls the morphogenesis of cardiac valves, is expressed in the developing lymphatic vasculature and intraluminal valves. Our data from primary LECs show that PROX1, at least in part, controls the LEC-specific expression of NFATc1, whereas the lymphangiogenic growth factor VEGF-C induces NFATc1 nuclear translocation through activation of VEGFR-2. The relative extent of the contribution of VEGFR-2--VEGFR-2 homodimeric versus VEGFR-2--VEGFR-3 heterodimeric complexes to NFATc1 activation remains to be determined; however, the inability of VEGFR-3 signaling alone to activate NFATc1 nuclear translocation suggests that in the lymphatic endothelium VEGFR-2-- or VEGFR-2--VEGFR-3--mediated pathways are more important for the establishment of collecting vessel phenotype rather than for the formation of a capillary network. In agreement with this hypothesis, VEGFR-2 is highly expressed in collecting lymphatic vessels and valves ([@bib66]; [@bib86]; unpublished data) where it promotes lymphatic vessel enlargement, whereas VEGFR-3 signaling is responsible for capillary sprouting ([@bib86]).

In addition to its role in endocardial cells, NFAT signaling in the blood vascular endothelium is important for cell proliferation, expression of proinflammatory genes, vascular patterning during early embryogenesis, and angiogenesis under pathological conditions ([@bib70]; for review see [@bib11]). Our in vivo data, from *Nfatc1*-deficient mice and after inhibition of NFAT activation by CsA, show that the calcineurin/NFAT pathway does not contribute to angiogenesis at late stages of embryonic development, nor does it affect LEC commitment. Instead, loss of NFAT signaling impairs the maturation and remodeling of the lymphatic vasculature as indicated by persistent expression of lymphatic capillary markers, lymphatic vessel hyperplasia, reduced formation of lymphatic valves, and impaired sprouting. These phenotypes, reminiscent of the ones observed in *Foxc2*^−/−^ mice, are strongly enhanced upon loss of one *Foxc2* allele, suggesting a genetic interaction between these two pathways. However, in CsA-treated mice, Foxc2 expression is high in all LECs, whereas NFATc1 expression is normal in *Foxc2*-deficient mice. These results indicate that Foxc2 and NFATc1 are expressed independently of each other and suggest that they act by coregulating transcription of downstream genes.

To gain mechanistic understanding of the role of FOXC2 in LECs, we performed a genome-wide analysis of FOXC2-binding sites. Previous studies suggested several FOXC2 target genes in blood vascular endothelium based on computational analysis of proximal promoters ([@bib23],[@bib24]; [@bib25]). In this report, we have studied the association of FOXC2 across the entire genome, and we show that the vast majority of FOXC2-binding sites are located in the intergenic and intronic regions, arguing that FOXC2 acts primarily via distal enhancers as previously observed for estrogen-related receptor α and FOXa1 ([@bib7]; [@bib43]). The analysis of FOXC2 ChIP sequences demonstrated that NFAT-binding sites are strongly enriched in the proximity of FOXC2-binding sites. Based on this observation, we experimentally confirmed that NFATc1 binds to FOXC2 ChIP-derived fragments containing NFAT consensus and that it can direct transcription in reporter assays, thus providing the molecular basis for the NFAT and FOXC2 cooperation in vivo. The outstanding remaining question concerns the identification of FOXC2/NFATc1 effector genes or pathways responsible for establishment of the lymphatic collecting vessel phenotype. Future studies, including the combination of ChIP-chip data with chromosome capture analysis, gene expression profiling of *Foxc2*-deficient LECs, and large-scale screening studies in small vertebrate models of lymphatic vascular development, such as zebrafish or *Xenopus laevis*, will be invaluable to answer these questions.

In conclusion, our data provide a new understanding of the developmental regulation of lymphatic vessels and the role of Foxc2 in establishing a collecting vessel identity and introduce a novel role for the transcription factor NFATc1 in lymphatic development. Based on our findings, we propose a model for the role of Foxc2 and NFATc1 in establishing the identity of collecting lymphatic vessels. During normal lymphatic development, maturing lymphatic vessels up-regulate Foxc2, and VEGF-C--VEGFR-2/3 signaling activates NFATc1, which together start a genetic program for formation of collecting vessels. Deficiency in either *Foxc2* or active NFATc1 in the lymphatic endothelium affects the expression of target genes, shutting down the program for establishment of a collecting vessel identity and leading to a persistent capillary-like phenotype. As damage to collecting vessels is a leading cause of secondary lymphedema, which frequently develops after cancer surgery--associated lymph node dissection, our data suggest that therapeutic delivery of FOXC2 and constitutively active NFATc1 could represent a strategy for treatment of secondary lymphedema through enhanced regeneration of collecting lymphatic vessels.

Materials and methods
=====================

Animal models and in vivo analyses
----------------------------------

Animal experiments were approved by the National Animal Ethics Committee and were performed in accordance with institutional guidelines. *Foxc2^−/−^* mice were bred on the ICR background and genotyped as described previously ([@bib28]; [@bib59]). *NFATc1^−/−^*, *Angpt2^+/lacZ^*, TOP-Gal mice, and BAT-Gal mice have been described previously ([@bib62]; [@bib12]; [@bib19]; [@bib50]). For experiments involving only wild-type mice, outbred ICR or NMRI mice were used. Embryonic age was determined according to the day of the vaginal plug (E0.5). For NFAT inhibition, E12.5--16.5 pregnant mice were given 50 mg/kg CsA (EMD) in 10% DMSO in sunflower seed oil (Sigma-Aldrich) or DMSO in oil only twice a day by oral gavage.

For fluorescent lymphangiography, embryos were injected with 10 mg/ml FITC-dextran in PBS (2,000-kD molecular mass; Sigma-Aldrich) subcutaneously in the hind limbs immediately after dissection, and flank collecting lymphatic vessels were visualized by fluorescence microscopy.

Antibodies, staining procedures, and image acquisition
------------------------------------------------------

Mesenteries and skins were dissected, fixed in 4% PFA, and whole-mount staining was performed as described previously ([@bib65]; [@bib75]). 6-µm deparaffinized tissue sections were subjected to heat-induced epitope retrieval (High pH Retrieval Solution; Dako). Cultured cells were fixed with 4% PFA, permeabilized with 0.1% Triton X-100, and blocked with 5% donkey serum. For stainings, we used rat anti--mouse Foxc2 ([@bib18]), mouse anti--human NFATc1 (clone 7A6; Santa Cruz Biotechnology, Inc.; [@bib77]), rabbit anti--human PROX1 ([@bib35]), goat anti--mouse VEGFR-3 (R&D Systems), rabbit anti--mouse LYVE-1 ([@bib59]), rat anti--mouse PECAM-1 (BD), rabbit anti--mouse NG2 (Millipore), Cy3-conjugated mouse anti--human α-SMA (Sigma-Aldrich), rabbit anti--mouse collagen IV (Cosmo Bio), and goat anti--mouse SLC (R&D Systems). Alexa Fluor 488, 594, and 647 fluorochrome-conjugated secondary antibodies (Invitrogen) were used for signal detection. The tyramide signal amplification method (Tyramide Signal Amplification Indirect; PerkinElmer) was used for the detection of VEGFR-3 after in situ hybridization.

Samples were mounted with DAPI-containing Vectashield (Vector Laboratories) and analyzed at room temperature with a confocal microscope (LSM 510 Meta; Carl Zeiss, Inc.) using LSM AIM software or an epifluorescent microscope (Axioplan 2; Carl Zeiss, Inc.) equipped with a charge-coupled device camera (AxioCam HRc; Carl Zeiss, Inc.) using Axiovision software (version 4.6; Carl Zeiss, Inc.). Objectives used were 10× Plan-Apochromat NA 0.45, 10× Fluar NA 0.5, 10× Plan-Neofluar NA 0.3, 20× Plan-Neofluar NA 0.5, 40× Plan-Apochromat NA 1.3, 40× long-distance C-Apochromat NA 1.1, and 40× Plan-Neofluar NA 0.75 (Carl Zeiss, Inc.). Three-dimensional projections of whole-mount images were digitally reconstructed from confocal z stacks using LSM AIM software and processed using Photoshop (CS; Adobe). Images are representative pictures from three to five embryos/stage or phenotype.

In situ hybridization
---------------------

Frozen sections or whole-mount mesenteries from E17.5 embryos were used and processed as described previously ([@bib85]). Sections were hybridized with complementary RNA anti-sense or sense probes for *Angpt2* (nucleotides 45--738 from GenBank under accession no. [NM_007426](NM_007426)), *NFATc1* (nucleotides 1,012--1,519 from GenBank under accession no. [NM_016791](NM_016791)), or *Prox1* (nucleotides 276--1,208 from GenBank under accession no. [NM_002763](NM_002763)).

Cell culture, transfections, transductions, and luciferase reporter assays
--------------------------------------------------------------------------

Human iLECs were isolated as described previously ([@bib22]; [@bib29]) and cultured in endothelial cell growth medium (PromoCell). Lymphatic endothelial identity was confirmed with PROX1 staining. For growth factor treatments, iLECs were starved for 6 h, treated with 200 ng/ml CsA (EMD) in DMSO or only DMSO for 2 h in starvation medium, and stimulated with 200 ng/ml ΔNΔC VEGF-C ([@bib36]), 500 ng/ml ΔNΔC VEGF-C(C156S) ([@bib26]), and 500 ng/ml VEGF-E NZ7 ([@bib20]) for 20 min. For siRNA experiments, iLECs were transfected with 10--40 nM siRNA using Lipofectamine 2000 (Invitrogen) and the following siRNAs: PROX1, 5′-CUAUGAGCCAGUUUGAUAUUU-3′ (Thermo Fisher Scientific); FOXC2, 5′-AGGTGGTGATCAAGAGCGAUU-3′; or siRNA Allstars Control (Invitrogen). Cells were lysed 48--96 h after transfection. For adenoviral experiments, iLECs were transduced with 20--50 plaque-forming unit/cell recombinant adenoviruses encoding human PROX1 ([@bib60]), FOXC2 ([@bib59]), or LacZ ([@bib41]) in serum-free medium for 1 h and lysed 48 h after transfection. For luciferase reporter assays, 183--199-bp sequences from selected ChIP peak regions were subcloned into pTA luciferase reporter vector. 293T cells were cotransfected with reporter constructs and constitutively active NFATc1 (plasmid 11102; Addgene; [@bib54]), FOXC2 ([@bib59]), and empty vectors using jetPEI transfection reagent (Polyplus-Transfection). Renilla luciferase pCMV-RL (provided by C. Heckman, University of Helsinki, Helsinki, Finland) was used for normalization of transfection efficiency. 48 h after transfection, cells were lysed and analyzed using Dual-Luciferase kit (Promega). Mutations in FOXC2-binding sites in fragment 8 were introduced using site-directed mutagenesis with the following primers: NFAT mutant, 5′-CAAAAACACACTCCAACCTTTCC-3′ and 5′-GATGTAGGTCTAAGGGCGAATTC-3′; FOXC2 mutant 1, 5′-GACAGAAACCTATTATTGGAAACAATT-3′ and 5′-CGTTCAGGGTAGGAGAAGGGAAG-3′; FOXC2 mutant 2, 5′-GACAGGATTCATATATTTCATCC-3′ and 5′-CATAGACGTGTATGAAATAATTGTT-3′; and FOXC2 mutant 3, 5′-GACATGTCAAAATAGGAAGCCCA-3′ and 5′-CTTATTTCCTGGATGAAATATATGAATCCTGT-3′. The presence of mutations was verified by sequencing. Experiments were done in triplicate and repeated at least three times. Values are expressed as fold increase compared with empty control ± SD.

ChIP-chip analysis
------------------

ChIP-chip was performed essentially as described by [@bib56] with the following modifications: iLECs were cross-linked with formaldehyde in complete endothelial cell basal medium MV (PromoCell), and IP dilution buffer was substituted with 3% BSA containing complete inhibitor tablets (Roche). DNA was sheared using a sonicator (Soniprep 150; MSE) and immunoprecipitated using rat anti--mouse Foxc2 antibody ([@bib18]) complexed with protein G--Sepharose (GE Healthcare). Decross-linked ChIP DNA was amplified using GenomePlex Complete Whole Genome Amplification kit (Sigma-Aldrich) using the buffer supplemented with deoxynucleotide-triphosphate + deoxy-UTP mixture. DNA was fragmented using uracil DNA glycosylase and apurinic/apyrimidinic endonuclease. Terminal labeling, hybridization, and array processing were performed as recommended by the array manufacturer (Affymetrix). Three biologically independent ChIP replicates and two control IgG replicates were hybridized to GeneChip Human Tiling 2.0R Array Sets (Affymetrix). Data analysis was performed using MAT software ([@bib33]) at 0.1% FDR cutoff (intensity analysis parameters: BandWidth = 300, MaxGap = 300, MinProbe = 10). A total of 2,359 FOXC2-enriched regions were identified of which nine mitochondrial sequences were discarded from further analysis. Enriched regions were visualized using Integrated Genome Browser software (Affymetrix). Initial analyses of evolutionary conservation, nearby genes, and enriched transcription factor--binding motifs were performed using cis-regulatory element annotation system (CEAS) software ([@bib31]).

Bioinformatics analyses of ChIP-chip data
-----------------------------------------

400-bp-long fragments from the center of each ChIP sequence were extracted and ranked according to the p-value. The fragments were split in 10 bins of 235 sequences each, with bin 1 containing the sequences with the lowest p-values and bin 10 containing the sequences with the highest p-values. De novo motif discovery was performed in each bin separately using the program MEME (multiple EM for motif elicitation; [@bib2]) in the mode of one occurrence per sequence and a motif width ranging from 7 to 15. MEME results were confirmed by the Gibbs sampler ([@bib76]) with default options.

The de novo--discovered FOXC2-binding site and all vertebrate transcription factor--binding sites stored as TRANSFAC matrices ([@bib51]) were turned into calibrated profiles using the *pftools* program ([@bib5]; [@bib64]). To select a stringency threshold defining binding site predictions of high quality, several score thresholds were applied to detect potential FOXC2-binding sites in the 2,350 ChIP sequences, and the threshold of 3.4 was selected, as it predicted a FOXC2-binding site in 80% of the sequences. This same threshold was then used to predict the positions of other transcription factor--binding sites such as NFAT. The NFAT matrix 1 has been derived from 26 experimentally identified endogenous NFAT-binding sites ([@bib37]), and the NFAT matrix 2 has been derived from a selection of the same sites used for matrix 1 plus eight additional TRANSCompel sites. The same 3.4 cutoff was used to compute random matches in 1,000 random sets, which were composed of randomly shuffled ChIP sequences with a window of 20 nucleotides. The enrichment, or fold change, was computed as the ratio of the number of ChIP matches and the mean number of random matches. The 95% confidence interval for the enrichment ratios was estimated assuming that the sampling distribution is approximately Gaussian for the log ratio and Poisson for the counts. For the analysis of putative PROX1-binding sites, the matrix for *Drosophila melanogaster* prospero was used ([@bib10]).

EMSA
----

25 µl EMSA reaction mixtures contained 10 mM Hepes, pH 8.0, 3 mM Tris--HCl, pH 8.0, 50 mM KCl, 2 mM MgCl~2~, 10% glycerol, 1 mM dithiotreitol, 0.04 mg/ml poly-deoxy-inosinic-deoxy-cytidylic acid, 0.4 mg/ml BSA, γ-^33^P--labeled DNA probe, and cell lysates or 0.8 µg recombinant human NFATc1 protein (SignalChem). For supershifts, 1 µg rat anti--mouse Foxc2, mouse anti--human NFATc1, or control antibodies from the same species were added to the reaction mixtures. After incubation for 30 min at room temperature, probes were loaded on 5% criterion Tris-Borate-EDTA polyacrylamide gel (Bio-Rad Laboratories). Electrophoresis was performed for 1--2 h at 10--20 mA/100--150 V. The gels were dried and visualized by autoradiography or using a phosphorimager.

Immunoprecipitation and Western and Northern blotting
-----------------------------------------------------

For analysis of protein interaction, 293T cells were cotransfected with HA-NFATc1 and FOXC2 expression vectors using Lipofectamine 2000 (Invitrogen). 48 h after transfection, cells were lysed with buffer containing 20 mM Tris, pH 7.8, 500 nM NaCl, 1% NP-40, and complete protease inhibitor mixture (Roche). The lysates were sonicated, spinned down, precleared with protein G--Sepharose beads (GE Healthcare), incubated overnight with anti-HA antibodies (Abcam) or control nonimmune rabbit IgG (Sigma-Aldrich), and incubated with protein G--Sepharose beads. The precipitates were washed with lysis buffer, resuspended in Laemmli sample buffer, and heated at 95°C for 10 min.

For Western blotting, samples were resolved by SDS-PAGE, transferred onto Immobilon-P membrane (Millipore), and blotted with monoclonal antibodies against Foxc2 ([@bib18]), NFATc1 (clone 7A6; Santa Cruz Biotechnology, Inc.), PROX1 (R&D Systems), phospho--VEGFR-2 (Tyr1175; Cell Signaling Technology), phospho-ERK1/2 (Cell Signaling Technology), and GAPDH (Europa Bioproducts). Western blots were developed using the ECL method (SuperSignal West Femto Maximum Sensitivity Substrate; Thermo Fisher Scientific).

For Northern analysis, 10 µg total RNA was separated in a 1% agarose gel, and blots were hybridized in ULTRAhyb solution (Applied Biosystems) with a ^32^P-labeled fragment of human *NFATc1* (nucleotides 2,577--2,825 from GenBank under accession no. [NM_006162](NM_006162)).

Quantification and statistical analysis
---------------------------------------

Mesenteric valves were identified as areas of strongly positive Prox1 staining and counted from duodenum to ileum (*n* = 4 for each genotype and treatment; E17.5). The mean vessel widths of dermal capillaries (*n* = 4) were calculated using Matlab (Mathworks) by dividing vessel area (determined by thresholding) by length (determined by a skeletonization algorithm by Nicholas R. Howe, Smith College, Northampton, MA). For colocalization of Foxc2 and NFATc1, LECs were counted from nine different lymphatic vessels from paraffin sections of three wild-type E17.5 embryos. For analysis of nuclear NFATc1 intensity in LECs, RGB images were analyzed with the CellCounter program (developed by V. Rantanen, Molecular Imaging Unit, University of Helsinki). Values were counted from nuclear NFATc1 staining and expressed as mean percentual intensity of maximum pixel intensity. A two-tailed, unpaired Student\'s *t* test was performed to determine statistical significance by the probability of difference between the means.

Online supplemental material
----------------------------

Fig. S1 shows LEC clusters and filopodia in the developing mouse mesentery at E14.5 and heterogeneous expression of LYVE-1 in embryonic mesentery and skin during development. Fig. S2 shows analysis of *NFATc1* expression by in situ hybridization, colocalization with Foxc2, inhibition of NFATc1 nuclear translocation, and Foxc2 expression in CsA-treated mice. Fig. S3 shows activation of ERK1/2 phosphorylation by wild-type and mutant growth factors, equal *NFATc1* mRNA levels in iLECs after growth factor stimulation, and an increase in overall NFATc1 expression upon PROX1 overexpression, coimmunoprecipitation of FOXC2, and NFATc1. Fig. S4 shows Western blots of FOXC2 ChIP experiments, binding of FOXC2 to ChIP targets in EMSA, which is abolished by mutations in FOXC2-binding sites, and a table with ChIP region fragments used in EMSAs and luciferase reporter assays. The supplemental data contains the CEAS annotation results of all FOXC2 ChIP sequences, whereas Table S1 shows FOXC2 ChIP regions that also were found to contain NFAT-binding sites. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.200901104/DC1>.
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